Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (noted as Scinai Immunotherapeutics Ltd. in metadata) covers the month of June 2015. The report details an immediate disclosure originally published on the Tel-Aviv Stock Exchange on May 31, 2015, regarding executive compensation adjustments and equity grants approved by the Board of Directors.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on human resources and equity compensation matters.
Material Changes
The primary material changes involve executive compensation and equity grants approved on May 26 and May 28, 2015:
- CEO Compensation: Dr. Ron Babecoff's monthly salary increased from NIS 52,500 to NIS 80,000 (approximately $20,618 USD).
- CSO Compensation: Ms. Tamar Ben Yedidia's monthly salary increased from NIS 27,300 to NIS 39,700 (approximately $10,230 USD).
- CEO Equity Grant: Dr. Babecoff was granted unregistered options equal to 5% of the company's issued and outstanding capital on a fully diluted basis as of May 21, 2015.
- Employee Equity Grant: A total of 3,780,000 options were granted to employees, including 500,000 to the CFO (Mr. Uri Ben Or) and 500,000 to the Chief Scientific Officer (Ms. Tamar Ben Yedidia).
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The following contingencies and risks are noted:
- Regulatory Approvals: The compensation terms and option grants are subject to required legal approvals, including approval from the general meeting of shareholders and the Tel-Aviv Stock Exchange (TASE).
- Option Terms: All granted options vest over a period of three years and expire 10 years from the grant date. The exercise price is set at 130% of the average sale share price on TASE during the 30 trading days prior to approval.
Investor Verification Checklist
- Verify the final approval status of the option grants by the general meeting of shareholders and TASE.
- Confirm the exact number of shares underlying the CEO's 5% grant once the fully diluted capital count is finalized.
- Monitor future filings for the formal grant notices required by law for the employee options.
- Review the company's 2005 Israeli Share Option Plan to ensure the grants comply with existing plan limits.